I-antibiotics yangoku esetyenziswa kwiklinikhi, ukongeza kwi-neutralizing pathogens ekujoliswe kuyo nayo ilimaza ibhaktheriya enempilo emathunjini. Ukuphazamiseka kwi-gut microbiome kuneziphumo eziyityhefu kwisibindi, izintso kunye namanye amalungu. Lo ngumba oza kuqwalaselwa. Abaphandi baye bafumanisa i-lolamicin, umviwa we-antibiotic oye wafunyaniswa esebenza ngokuchasene nosulelo lwegram-negative ngaphandle kokuchaphazela impilo ye-gut microbiome kwizifundo zangaphambi kweklinikhi. Obu bubungqina bokuba i-antibiotics ebulala i-pathogenic microbes ngelixa igcina ibhaktheriya enenzuzo emathunjini inokuphuhliswa usulelo lwegram-negative. Inika ithemba lokujongana neengxaki ezinxulumene nokujoliswa okungakhethiyo kweebhaktheriya zegram-negative. Nangona kunjalo, iminyaka yophando olongezelelweyo iyafuneka ngaphambi kokuba ifike kwinqanaba lokusetyenziswa kweklinikhi.
uninzi antibiotics kujoliswe kuphela kwiibhaktheriya ezinegram-positive okanye kujoliswe kuzo zombini iibhaktheriya zegram-positive kunye negram-negative. Abanye antibiotics ezithile kwiibhaktheriya zegram-negative (iibhaktheriya zegram-negative zine-double layer of protection kudonga lweseli yazo eyenza kube nzima ukuyibulala) iphinda ibulale iintsholongwane zegram-negative eziluncedo emathunjini. Iziphazamiso kwi-gut microbiome zidalwe ngolo hlobo zifunyenwe zinetyhefu / iziphumo ezibi ngakumbi kwisibindi kunye nezintso. Yiyo loo nto imfuneko yokuphuhlisa amayeza okubulala iintsholongwane anokuthi abulale iibhaktheriya ze-pathogenic ngelixa ugcina ezo ziluncedo. Njengoko kuchaziwe kwiphepha lophando lwakutsha nje, izazinzulu ziye zaphuhlisa amayeza okubulala iintsholongwane abizwa ngokuba yi-lolamicin efunyenwe ngokukhetha i-gram-negative pathogenic bacteria ngelixa igcina ezo ziluncedo.
I-Lolamicin yi-inhibitor ye-Lol (indawo ye-lipoproteins) indlela, inkqubo ye-lipoprotein-transport efunyenwe ngokukodwa kwiibhaktheriya zegram-negative ezihluke kwi-genetically kwi-pathogenic kunye ne-bacteria enenzuzo.
Kwinkcubeko yeeseli, yayingenayo impembelelo exabisekileyo kwiibhaktheriya zegram-positive. Kwidosi eziphezulu, iye yanciphisa ukuya kutsho kwi-90% ye-E. coli enganyangekiyo ngamachiza amaninzi, i-K. pneumoniae kunye ne-E. cloacae Clinical isolates.
Ukulawulwa ngomlomo kwe-lolamicin kwiigundane ezine-septicemia enganyangekiyo ngamachiza okanye inyumoniya yahlangula i-100% yeempuku ezine-septicemia kunye ne-70% yeempuku ezinenyumoniya. Ngapha koko, ulawulo lwe-lolamicin aluzange lukhokelele kulo naluphi na utshintsho olukhulu ekubunjweni kwe-taxonomic yeebhaktheriya kwi-gut microbiome yeempuku ngexesha lonyango lweentsuku ezintathu okanye olu lulandelayo lweentsuku ezingama-28.
Ezi ziphumo zezifundo zezilwanyana zangaphambi kweklinikhi zikhuthaza kwaye zinika ithemba lokujongana neengxaki ezinxulumene nokujoliswa okungakhethiyo kwiibhaktheriya zegram-negative. Ibubungqina bengcamango yokuba kunokwenzeka ukuphuhlisa antibiotics ezijolise ngokukhethekileyo kwiibhaktheriya ezinobungozi zegram-negative ngelixa zigcina i-microbiome yamathumbu kuyo nayiphi na imiphumo emibi. Nangona kunjalo, iminyaka yophando olongezelelweyo iyafuneka ukwandisa iziphumo.
***
Iingxelo:
- Muñoz, KA, Ulrich, RJ, Vasan, AK et al. I-antibiotic ye-Gram-negative-selective egcina i-gut microbiome. Indalo 630, 429-436 (2024). Ipapashwe: 29 May 2024. DOI: https://doi.org/10.1038/s41586-024-07502-0
- IYunivesithi yase-Illinois Urbana-Champaign 2024. Iindaba zophando - I-antibiotic entsha ibulala ibhaktheriya ye-pathogenic, igcina iintsholongwane eziphilileyo zamathumbu. Ithunyelwe nge-29 kuMeyi 2024. Iyafumaneka e https://news.illinois.edu/view/6367/668002791
***
